Search

Your search keyword '"José M. Huguet"' showing total 4 results
Start Over Author "José M. Huguet" Topic hepatology
4 results on '"José M. Huguet"'

1. 133 - PATRÓN DE PRESCRIPCIÓN DE PROBIÓTICOS ADYUVANTES A LA TERAPIA ERRADICADORA FRENTE A HELICOBACTER PYLORI: RESULTADOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI (HP-EUREG)

Author

Diego Casas, Javier Alcedo, Miguel Lafuente, F. Javier López, Angeles Pérez-Aisa, Matteo Pavoni, Ilaria Maria Saracino, Bojan Tepes, Laimas Jonaitis, Manuel Castro-Fernández, Manuel Pabón-Carrasco, Alma Keco-Huerga, Irina Voynovan, Luis Bujanda, Alfredo J. Lucendo, Natasa Brglez Jurecic, Maja Denkovski, Perminder S. Phull, Luis Rodrigo, Angel Lanas, Samuel J. Martínez-Domínguez, Enrique Alfaro, Galina D Fadieienko, José M. Huguet, Dmitry S. Bordin, Antonio Gasbarrini, Juozas Kupcinskas, Gülüstan Babayeva, Oleksiy Gridnyev, Mrcis Leja, Theodore Rokkas, Ricardo Marcos-Pinto, Frode Lerang, Doron Boltin, Veronika Papp, Ante Tonki, Sinead M. Smith, Halis Simsek, Marino Venerito, Lyudmila Boyanova, Vladimir Milivojevic, Lumir Kunovsky, Tamara Matysiak-Budnik, Wojciech Marlicz, Michael Doulberis, Anna Cano-Català, Luis Hernández, Leticia Moreira, Olga P. Nyssen, Francis Megraud, Colm O. Morain, and Javier P. Gisbert

Subjects
Hepatology, Gastroenterology
Published
2023
Full Text
View/download PDF

2. LA ADMINISTRACIÓN DE LA TERAPIA CUÁDRUPLE CON BISMUTO EN CÁPSULA ÚNICA TRES VECES AL DÍA AUMENTA LA EFICACIA EN COMPARACIÓN CON LA PAUTA CONVENCIONAL DE CUATRO DOSIS DIARIAS: RESULTADOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI (HP-EUREG)

Author

Ángeles Pérez-Aísa, Olga P. Nyssen, Alma Keco-Huerga, Luis Rodrigo, Alfredo J Lucendo, Blas José Gómez Rodríguez, Juan Ortuño, Mónica Perona, José M. Huguet, Óscar Núñez, Luis Fernández-Salazar, Jesús Barrio, Ángel Lanas, Eduardo Iyo, Pilar Mata Romero, Miguel Fernández- Bermejo, Barbara Gomez, Ana Garre, Judith Gomez-Camarero, Luis Javier Lamuela, Ana Campillo, Luisa C de la Peña-Negro, Manuel Dominguez-Cajal, Luis Bujanda, Diego Burgos-Santamaria, Fernando Bermejo, Víctor González-Carrera, Ramón Pajares, Pedro Almela Notari, Javier Tejedor-Tejada, Montserrat Planella, Itxaso Jiménez, Yolanda Arguedas Lázaro, Antonio Cuadrado-Lavín, Isabel Pérez-Martínez, Edurne Amorena, Jesús M González- Santiago, Teresa Angueira, Virginia Flores, Samuel Jesús Martínez-Domínguez, Manuel Pabón-Carrasco, Benito Velayos, Alicia Algaba, Consuelo Ramírez, Enrique Alfaro Almajano, Manuel Castro-Fernández, Noelia Alcaide, Patricia Sanz Segura, Anna Cano-Català, Natalia García- Morales, Leticia Moreira, Francis Mégraud, Colm O’Morain, Xavier Calvet, and Javier P. Gisbert

Subjects
Hepatology, Gastroenterology
Published
2023
Full Text
View/download PDF

3. PAPEL DEL USO DE PROBIÓTICOS EN LA EFECTIVIDAD DE LOS TRATAMIENTOS FRENTE A HELICOBACTER PYLORI: RESULTADOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI (HP-EUREG)

Author

Diego Casas, Javier Alcedo, Miguel Lafuente, F. Javier López, Angeles Pérez-Aisa, Matteo Pavoni, Ilaria Maria Saracino, Bojan Tepes, Laimas Jonaitis, Manuel Castro-Fernández, Manuel Pabón Carrasco, Alma Keco- Huerga, Irina Voynovan, Luis Bujanda, Alfredo J. Lucendo, Natasa Brglez Jurecic, Maja Denkovski, Perminder S. Phull, Luis Rodrigo, Angel Lanas, Samuel J. Martínez-Domínguez, Enrique Alfaro, Galina D Fadieienko, José M. Huguet, Dmitry S. Bordin, Antonio Gasbarrini, Juozas Kupcinskas, Gülüstan Babayeva, Oleksiy Gridnyev, Mrcis Leja, Theodore Rokkas, Ricardo Marcos-Pinto, Frode Lerang, Doron Boltin, Veronika Papp, Ante Tonki, Sinead M. Smith, Halis Simsek, Marino Venerito, Lyudmila Boyanova, Vladimir Milivojevic, Lumir Kunovsky, Tamara Matysiak-Budnik, Wojciech Marlicz, Michael Doulberis, Anna Cano-Català, Luis Hernández, Leticia Moreira, Olga P. Nyssen, Francis Megraud, Colm O. Morain, and Javier P. Gisbert

Subjects
Hepatology, Gastroenterology
Published
2023
Full Text
View/download PDF

4. Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn's disease: Results from the ENEIDA registry

Author

Míriam Mañosa, Agnès Fernández-Clotet, Pilar Nos, María Dolores Martín-Arranz, Noemí Manceñido, Ana Carbajo, Esther Hinojosa, Alejandro Hernández-Camba, Roser Muñoz-Pérez, Maia Boscá-Watts, Marta Calvo, Mónica Sierra-Ausín, Eugenia Sánchez-Rodríguez, Manuel Barreiro-de Acosta, Alejandro Núñez-Alonso, Yamile Zabana, Lucía Márquez, Javier P Gisbert, Jordi Guardiola, Empar Sáinz, Pedro Delgado-Guillena, David Busquets, Manuel van Domselaar, Eva Girona, Rufo Lorente, Diego Casas-Deza, José M. Huguet, Sergio Maestro, M. José Cabello, Jesús Castro, Marisa Iborra, Fiorella Cañete, Margalida Calafat, and Eugeni Domènech

Subjects
Treatment Outcome, Crohn Disease, Hepatology, Gastroenterology, Humans, Ustekinumab, Tumor Necrosis Factor Inhibitors, Registries, Retrospective Studies
Abstract

BACKGROUND: Anti-TNF agents are the only effective biological agents for the prevention of postoperative recurrence (POR) in Crohn's disease (CD). However, they are contraindicated or have been shown to fail in some patients. Although ustekinumab and vedolizumab were licensed for CD some years ago, data in this setting are scarce.; METHODS: All CD patients in whom ustekinumab or vedolizumab was prescribed for the prevention of POR within three months of ileocolonic resection with anastomosis were identified from the ENEIDA registry. The development of endoscopic, clinical and surgical POR was registered.; RESULTS: Forty patients were treated for the prevention of POR with ustekinumab and 25 were treated with vedolizumab. Eighty per cent had at least one risk factor for POR (prior resections, active smoking, perianal disease or penetrating disease behaviour). All the patients had been exposed to anti-TNF therapy. After a median follow-up of 17 and 26 months, the cumulative probability of clinical POR at 12 months after surgery was 32% and 30% for ustekinumab and vedolizumab, respectively. Endoscopic assessment within the first 18 months after surgery was available for 80% of the patients on ustekinumab and 70% for those on vedolizumab. The rate of endoscopic POR was 42% for ustekinumab and 40% for vedolizumab. One patient treated with ustekinumab and two with vedolizumab underwent a new intestinal resection.; CONCLUSIONS: Ustekinumab and vedolizumab seem to be effective in the prevention of POR in patients at high risk. Our results warrant controlled trials comparing these drugs with conventional therapies. Copyright © 2022. Published by Elsevier Ltd.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results